Gadicke Ansbert 的 Form 4 申報
Werewolf Therapeutics, Inc.（HOWL），2025/12/4 申報
- 申報編號
- 0001231919-25-000574
- 申報時間
- 2025/12/4 18:18 ET
- 交易日
- 2025/12/2-12/4
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
這份申報列了 3 筆非衍生性交易。公開市場賣出合計 $18.3 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 其他：Former 10% Owner |
| MPM Asset Management LLCCIK 0001263048 | 其他：Former 10% Owner |
| MPM BioImpact LLCCIK 0001687078 | 其他：Former 10% Owner |
| UBS Oncology Impact Fund L.P.CIK 0001691428 | 其他：Former 10% Owner |
| MPM Oncology Innovations Fund LPCIK 0001719960 | 其他：Former 10% Owner |
| Oncology Impact Fund (Cayman) Management L.P.CIK 0001721036 | 其他：Former 10% Owner |
| MPM Oncology Innovations Fund GP LLCCIK 0001857903 | 其他：Former 10% Owner |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2014, L.P.